Study of SRF114 in Patients With Advanced Solid Tumors
Head/Neck
Head/Neck
This is a Phase 1/2, open-label, first-in-human, dose-escalation and expansion study of
SRF114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid
tumors.
SRF114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid
tumors.
Head/Neck
I
Choe, Jennifer
NCT05635643
VICC-DTHAN23184P
